NCT06111521View on ClinicalTrials.gov

A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 27, 2023

Primary Completion Date

April 1, 2024

Study Completion Date

April 1, 2024

Conditions
Healthy
Interventions
DRUG

LY3537982

Administered orally

DRUG

Digoxin

Administered orally

DRUG

Rosuvastatin

Administered orally

DRUG

Midazolam

Administered orally

DRUG

Midazolam

Administered IV

Trial Locations (1)

84124

ICON Early Clinical & Bioanalytical Solutions, Salt Lake City

Sponsors

Collaborators (1)

Loxo Oncology, Inc.
All Listed Sponsors
collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT06111521 - A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants | Biotech Hunter | Biotech Hunter